Lymphedema in patients with X-linked severe combined immunodeficiency

X连锁重症联合免疫缺陷患者的淋巴水肿

阅读:1

Abstract

BACKGROUND: IL2RG and JAK3 mutations cause T-cell-negative, B-cell-positive, natural killer cell-negative severe combined immunodeficiency (SCID). Cell therapies such as hematopoietic stem cell transplantation (or gene therapy for IL2RG deficiency) can effectively restore T-cell immunity but-when performed without myeloablation-may leave residual immune defects. These include persistent B-cell dysfunction, poor innate lymphoid cell recovery, and poor reconstitution of secondary lymphoid organs. Severe/recurrent warts may also occur in the long term. OBJECTIVE: We present 3 IL2RG SCID cases complicated by lymphedema and discuss possible hypotheses of this rare complication. METHODS: We describe 3 patients with IL2RG SCID who developed lymphedema: 2 after unconditioned cell therapy and 1 with a hypomorphic mutation who remained untreated. Clinical presentation, immunologic data, imaging, and transplant history were reviewed and compared with published data. RESULTS: Lymphedema affected the lower limbs and varied in severity, with one case complicated by recurrent dermohypodermitis and Streptococcus mitis sepsis. CONCLUSION: Lymphedema is a rare but potentially disabling complication of IL2RG/JAK3 SCID, affecting long-term quality of life. Hypothetically, low/absent levels of innate lymphoid cells-particularly lymphoid tissue inducer cells, a subset of innate lymphoid cells-may be a contributing factor in the pathogenesis of lymphedema in IL2RG/JAK3 SCID.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。